415
Participants
Start Date
October 31, 2005
Primary Completion Date
April 30, 2007
Study Completion Date
April 30, 2007
Lapaquistat acetate and rosuvastatin
Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Lapaquistat acetate and rosuvastatin
Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Rosuvastatin
Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Birmingham
Haleyville
Mobile
Scottsdale
Long Beach
Mission Viejo
Orange
Redondo Beach
Rolling Hills Estates
San Diego
Torrance
Tustin
Avon
Bristol
DeLand
Fort Lauderdale
Hialeah
Jacksonville
Jupiter
Melbourne
Miami
Naples
Ocala
Pembroke Pines
Plantation
Hayden Lake
Meridian
Arlington Heights
Aurora
Chicago
Peoria
Indianapolis
Iowa City
Kansas City
Witchita
Louisville
Thibodaux
Auburn
Haverhill
Benzonia
Detroit
Kansas City
St Louis
Missoula
Concord
West Seneca
Raleigh
Statesville
Winstom-Salem
Grand Forks
Akron
Cincinnati
Columbus
Kettering
Tulsa
Eugene
Portland
Lansdale
Philadelphia
Pittsburgh
Scotland
Cranston
Anderson
Bristol
Cordova
Kingsport
Austin
Dallas
Houston
McKinney
Midland
San Antonio
Salt Lake City
Burke
Norfolk
Richmond
Weber City
Bellevue
Burien
Edmonds
Seattle
Spokane
Calgary
Portage la Prairie
London
Oakville
Oshawa
Thornhill
Toronto
Chicoutimi
Saint-Jérôme
Ste-Foy
Lead Sponsor
Takeda
INDUSTRY